Figure 6.

The hexatherapy treatment regimen reduces PMN-MDSC and improves effector T cell-to-Treg cell ratios in the 4T1 tumor microenvironment. (A–C) Primary tumors (n=4–5/group) from figure 4B, C were collected on day 28 post-tumor implantation (7 days after the last treatment) and were assessed through flow cytometry for frequency of (A) PMN-MDSC (CD11b⁺Ly6G⁺Ly6C^lo), (B) M-MDSC (CD11b⁺Ly6G⁻Ly6C^high), and (C) Tregs (FoxP3⁺CD4⁺ T cells) in the CD45⁺ population. (D, E) Flow cytometric analysis was used to determine the (D) CD4-to-Treg ratio and (E) CD8-to-Treg ratio in the tumor. Analysis of variance with Tukey’s post hoc test. Error bars, SEM. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. M-MDSC, mononuclear myeloid derived suppressor cell; PD-L1, programmed death-ligand 1; PMN-MDSC, polymorphonuclear MDSC; Treg, regulatory T cell.